When we talk about early identification, we are talking about an ALREADY EXISTING INJURY, triggering a change in the patient's quality of life and a projection of future costs for the health system. INNOVATIVE ASPECT: While screening mammography identifies an existing lesion, VTM could: Make an early diagnosis before the formation of a visible or palpable tumor mass; Check the metabolic activity in suspicious lesions identified by other diagnostic methods; Demarcate tumor range and tumor similarity from a distance in breast cancer. Regarding the Risk x Benefit:There are no medications incorporated, associated or administered by the equipment; There is no ionizing radiation incorporated or delivered by the equipment; There are no contraindications for the use of the equipment by the patient (Non-ionizing infrared radiation, without contrast or contact); Audience destined to operate the equipment: Physician / Radiologist with training Therefore, the research in question is of great relevance for such a debilitating health problem for the patient and for the health system.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Concordance of the diagnosis of abnormality during the VTM exam in relation to the standard exam (mammography);
Timeframe: [D2, approximately 60 days]
Frequency of non-visible vascular identification:
Timeframe: [D2, approximately 60 days]
Frequency of identifying non-visible textures
Timeframe: [D2, approximately 60 days]
Frequency of thermal discrepancy in nearby pixels in areas suspected of non-visible abnormalities:
Timeframe: [D2, approximately 60 days]
Frequency of sample changes detected by VTM
Timeframe: [D2, approximately 60 days]